Actively Recruiting
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Led by Chinese PLA General Hospital · Updated on 2026-05-08
160
Participants Needed
1
Research Sites
123 weeks
Total Duration
On this page
Sponsors
C
Chinese PLA General Hospital
Lead Sponsor
F
First Affiliated Hospital of Harbin Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML).
CONDITIONS
Official Title
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 14 to 75 years, any gender
- Newly diagnosed with intermediate- or high-risk acute myeloid leukemia (excluding M3 subtype)
- Liver function with ALT and AST 4 2.5 times the upper limit of normal; bilirubin 4 2 times the upper limit of normal
- Kidney function with creatinine at or below the upper limit of normal
- No uncontrolled infections, organ dysfunction, or severe mental illness
- ECOG performance status score between 0 and 2
- Predicted survival of at least 4 months
- No severe allergies
You will not qualify if you...
- Allergy or contraindication to any study drug
- Pregnant or breastfeeding women
- Known history of alcohol or drug addiction
- Mental illness or conditions preventing compliance with the study
- Less than 6 weeks since major organ surgery
- Liver function with ALT and AST above 2.5 times the upper limit of normal; bilirubin above 2 times the upper limit of normal
- Kidney function with creatinine above the upper limit of normal
- Considered unsuitable for the clinical trial due to poor compliance or substance abuse
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here